Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds

Researchers discovered that inhibiting a protein commonly targeted in asthma treatment boosts the effectiveness of cancer immunotherapy in laboratory studies. The finding opens a potential new avenue for treating cancers that resist current therapies, particularly aggressive breast cancers.

The protein in question plays a central role in asthma inflammation, but scientists identified it as a barrier to effective immune responses against tumors. By blocking this protein, researchers enhanced the ability of cancer-fighting immune cells to infiltrate and attack malignant tissue in preclinical models.

The work demonstrates a connection between respiratory disease pathways and cancer immunology that researchers had not previously exploited therapeutically. Existing asthma medications already target this protein safely in patients, meaning a translation pathway to clinical use potentially exists.

The team tested their approach in laboratory and animal models of breast cancer, including aggressive forms that typically respond poorly to standard immunotherapy. Results showed that combining protein blockade with checkpoint inhibitor immunotherapy, which removes the brakes on immune cells, produced superior tumor control compared to immunotherapy alone.

This represents early-stage research without human trials yet. Preclinical findings frequently fail to translate into clinical benefit, and safety profiles that work for asthma treatment may differ when applied to cancer patients. The researchers acknowledge these limitations while noting the logical foundation for pursuing further investigation.

The broader significance lies in revealing how mechanisms operating in non-cancer diseases can inform cancer treatment strategies. Asthma drugs are well-tolerated with established safety records, potentially reducing development timelines if clinical trials prove the approach works in patients. Aggressive breast cancers, particularly triple-negative variants, remain difficult to treat, making new therapeutic options valuable for oncology.

The team plans additional studies to understand the mechanism more thoroughly and determine optimal dosing and patient selection criteria. Clinical trials would follow only after rigorous preclinical validation. The next phase involves testing whether asthma medication derivatives